Drug Trial Radar · NCT07634198
A Clinical Study of YK-1169 Versus Ceftazidime-Avibactam in Adults With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia
Last checked: Nov 20, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
590
Planned (sponsor's estimate)
Start
Jun 4, 2026
Primary completion
Apr 1, 2028
Study completion Apr 1, 2028
Sponsor
- Lead sponsor
- Nanjing Yoko Biomedical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the all-cause mortality rate at Day 28 in the YK-1169 group versus the ceftazidime-avibatan injection group in the mITT population.
Conditions
- Hospital-acquired Bacterial Pneumonia (HABP)
- Ventilator-associated Bacterial Pneumonia (VABP)
Interventions
YK-1169Drug
Dissolve 2.5 g of YK-1169 in 0.9% saline solution to a total volume of 100 mL, and administer by intravenous infusion at a constant rate over 120 minutes (±15 min), once every 8 hours (±30 min); the total duration of treatment is 7 to 14 days.
Ceftazidime-avibactam InjectionDrug
Dissolve 2.5 g of ceftazidime-avibactam in 0.9% saline solution to a total volume of 100 mL, and administer by intravenous infusion at a constant rate over 120 minutes (±15 min), once every 8 hours (±30 min); the total duration of treatment is 7 to 14 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients with all-cause mortality in the mITT population at Day 28Time frame: Day 28
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.